Therefore, our findings further corroborate current CPIC and DPWG guidelines for CYP2C19 genotype-guided clopidogrel therapy in stroke/ TIA patients [12, 34], which provide evidence of a moderate strength recommendation of alternative antiplatelet agents for CYP2C19 LOF allele carriers and do not suggest specific recommendations according to patient’s ethnicity, although based primarily on evidence available in Asian patients. The gene discussed is CYP2C19; the disease is transient ischemic attack.